MSN Group to unveil drug to treat epilepsy
The Hindu
Drugmaker MSN Group is focussed on introducing generic products for various therapies at a fraction of the innovator’s product price once the patent expires.
“In the next 5-6 years, MSN will bring products, once the patent expires, at one-tenth of the cost,” executive director Bharat Reddy said, announcing that MSN will unveil anti-epilepsy drug Brivanext in India in the next few days.
More Related News